Skip to main content
. 2020 Jun 17;21(12):4301. doi: 10.3390/ijms21124301

Figure 1.

Figure 1

High expression of miR-941 in CD14+ monocytes from PsA patients. (A) The RNA samples were analyzed from (1) the healthy control group (HC), including two pooled samples from two males and one female, respectively; (2) the psoriasis group (PsO), including one pooled sample from two males; and (3) the psoriasis arthritis group (PsA), including two samples from two males and one female, respectively. MicroRNAs (miRNAs) with transcript per million (TPM) values more than 1000 in at least one sample and with average expression ratio (normal to disease or disease to normal) more than 1.5 are plotted on the heat map. (B) The microRNA expression level was presented in the unit of TPM. (C,D) The expression levels of miR-146b-5p and miR-941 were measured in HCs (n = 40), PsO patients (n = 40) and PsA patients (n = 40) by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Patients with PsA showed increased expression of miR-941 in CD14+ monocytes. (E) We set training model from miR-941 expression of CD14+ monocytes from patients with PsA, PsO, and HCs using a Support Vector Machine (SVM) learning algorithm. To distinguish PsA from PsO and HC, the value of auROC was 0.79, indicating that miR-941 expression can distinguish PsA patients from PsO and HCs with high accuracy. *** p < 0.001.